The scientific rationale of combining inhaled glucocorticoids and long acting beta 2 adrenoceptor agonists.
Asthma is characterised by a chronic inflammatory process involving the airway wall leading to airflow limitation and bronchial hyperresponsiveness. This review describes the cellular molecular events underlying airway inflammation and remodelling in asthma and focuses on the distinct mechanisms of action of corticosteroids in beta agonists in asthma pathophysiology. In particular it discusses the evidence from studies both in vitro and in vivo to suggest that there is a complimentary beneficial interaction of these agents on the asthma process.
Knox
Alan J
AJ
Division of Respiratory Medicine, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. alan.knox@nottingham.ac.uk
D000280:Administration, Inhalation; D000322:Adrenergic Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D058666:Adrenergic beta-2 Receptor Agonists; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000037:antagonists & inhibitors; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors; D006801:Humans; D016209:Interleukin-8 / Q000037:antagonists & inhibitors; D009126:Muscle Relaxation / Q000187:drug effects; D032389:Myocytes, Smooth Muscle / Q000378:metabolism / Q000473:pathology
D000322:Adrenergic Agonists; D058666:Adrenergic beta-2 Receptor Agonists; D018927:Anti-Asthmatic Agents; C515456:CCL11 protein, human; D054413:Chemokine CCL11; D019742:Chemokines, CC; D005938:Glucocorticoids; D016209:Interleukin-8; D016178:Granulocyte-Macrophage Colony-Stimulating Factor